← Russell 3000 cross-section

ACOG Alpha Cognition Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$215m
Revenue TTM
$15m
Net income TTM
$-23m
Free cash flow
$-31m
Composite score
Sector rank
#2838

Valuation

P / E
EV / EBITDA
EV / sales
11.3
FCF yield
-14.53%
Earnings yield vs 10-yr
-15.64pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-153.6%
EBITDA margin
ROE
-44.3%
ROIC
-251.3%
Revenue growth

Insider activity, last 90 days

Net open-market
$3.35m
Buyers
2
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Product Sales, Net Product revenue consists primarily of sales of the Company’s commercial product to wholesalers and pharmacies. Our revenue to date has been generated primarily from the upfront payment received from CMSI under the CMSI License Agreement. Cost of Product Sales Cost of product sales consists primarily of costs related to the manufacturing of ZUNVEYL, logistics costs, inventory impairment expense, royalty payments under license or purchase agreements, and amortization of the Alpha-1062 intellectual property intangible asset. …Alpha Cognition Inc., 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →